Stockreport

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to tr [Read more]